Expert Interview
Discussing BridgeBio’s infigratinib (BBP-831) in Cholangiocarcinoma
Ticker(s): BBIOA gastroenterologist with experience in cholangiocarcinoma, or cancer of the bile ducts.
Please tell us about your clinical experience. How many patients with cholangiocarcinoma do you see yearly? How often are FGFR2 genetic aberrations found, and what is the available choice of treatment?
How often do complications like local tumor progression, bile duct obstruction, liver failure or sepsis from cholangitis and abscesses occur?
How often does the cancer recur after surgery?
Can you talk to us about the mechanism of action of infigratinib - FGFR1-3 tyrosine kinase inhibitor?
In post second-line chemotherapy analysis, infigratinib reported an ORR of 26.9% (95% CI 16.8–39.1) and a DOR of 5.4 months (95% CI 3.7–7.4). How likely would you be to prescribe it in the future, judging from these results?
What chance of success do you think infigratinib could have in a front-line setting, administered as third- and later-line treatment?
Added By: slingshot_insightsAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
